ANAVEX Contracts FORENAP Pharma for Clinical Trials of ANAVEX 2-73 in Alzheimer’s Disease
Anavex Life Sciences Corp. has selected FORENAP Pharma EURL as the contract research organization (CRO). - October 02, 2009
Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I Alzheimer’s Disease Clinical Trials
Anavex Life Sciences Corp. today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. - September 23, 2009
Anavex Appoints Dr. Hervé De Kergrohen as CEO to Lead Company Through Clinical Trials and Future Growth
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) today announced the immediate appointment of Hervé de Kergrohen, MD, MBA, as its Chief Executive Officer (CEO) and director. Dr. de Kergrohen is an accomplished senior executive who has successfully founded and developed... - June 18, 2009
Anavex Appoints Leading Alzheimer's Disease Expert Dr. Mark Smith to Scientific Advisory Board
Anavex Life Sciences Corp. today announced the appointment of Dr. Mark A. Smith, Ph.D., FRCPath, to its scientific advisory board. - February 12, 2009
Anavex Scales Up Synthesis of Anavex 2-73 for Phase 1 Alzheimer’s Disease Study
Anavex Life Sciences Corp., (“ANAVEX”) (OTCBB: AVXL) has signed an agreement with organic chemistry services provider Syntagon AB (“Syntagon”) for the scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer’s disease. ANAVEX 2-73 is... - February 04, 2009
Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer's Compound ANAVEX 1-41 Published in Journal of Neuropsychopharmacology
Anavex Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, announces that the anti-amnesic and neuroprotective effects of ANAVEX 1-41 are detailed in a paper... - December 19, 2008
Anavex Presents Potent Neuroprotective Effects of Anavex 1-41 at Neuroscience 2008
Anavex Life Sciences Corp., a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, was selected to present its latest results with ANAVEX 1-41 at Neuroscience 2008, the 38th annual meeting of the Society... - December 17, 2008
Anavex Completes Successful Preclinical Studies on Lead Alzheimer's Drug Candidate
Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008
Anavex Presents Neuroprotective Effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008
Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008
Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA)
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity... - July 15, 2008
Anavex Further Strengthens Board of Directors
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and... - June 20, 2008
Anavex Announces Appointment of Oncology Specialist to Board of Directors, Changes to Executive Management
Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug... - May 23, 2008
Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008
Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008
Anavex Advances Drug Candidate for Treatment of Alzheimer's Disease
Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008
Anavex 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors
ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008
Anavex Strengthens Board of Directors
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008